PriceTargets.com logo

Silverback Therapeutics - SBTX Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$14.88 As of 04/17/2025 01:00 AM ET
+0 (0.00%)

This chart shows the closing price for SBTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
FebMarApr$14.88Closing price on 04/20/25:
Get New Silverback Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SBTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SBTX

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Silverback Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $14.88.

This chart shows the closing price for SBTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart
4/247/2410/241/254/255/26$4.11$7.89$12$15$19Closing price on 04/20/25: $14.88High$0.0000Average$0.0000Low$10.00M




Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Silverback Therapeutics. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/29/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/27/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/25/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/23/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/21/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/22/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/21/2025

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/13/2022Stifel NicolausLower Target$6.00 ➝ $5.00
4/1/2022The Goldman Sachs GroupDowngradeBuy ➝ Neutral
4/1/2022JonestradingDowngradeBuy ➝ Hold
4/1/2022Leerink PartnersDowngradeOutperform ➝ Market Perform
4/1/2022HC WainwrightDowngradeBuy ➝ Neutral
4/1/2022Stifel NicolausDowngradeBuy ➝ Hold$32.00 ➝ $6.00
11/12/2021Leerink PartnersLower TargetOutperform$42.00 ➝ $25.00
10/15/2021HC WainwrightReiterated RatingBuy$52.00
9/16/2021JonestradingReiterated RatingBuy$50.00
8/24/2021JonestradingReiterated RatingBuy$50.00
8/16/2021Leerink PartnersBoost TargetOutperform$46.00 ➝ $49.00
5/17/2021Leerink PartnersLower TargetOutperform$49.00 ➝ $46.00
4/6/2021Leerink PartnersBoost TargetOutperform$40.00 ➝ $49.00
3/30/2021Stifel NicolausBoost TargetBuy$58.00 ➝ $60.00
3/30/2021The Goldman Sachs GroupBoost TargetBuy$43.00 ➝ $48.00
12/29/2020Leerink PartnersInitiated CoverageOutperform$40.00
12/29/2020Stifel NicolausInitiated CoverageBuy$58.00
12/29/2020HC WainwrightInitiated CoverageBuy$44.00
12/29/2020The Goldman Sachs GroupInitiated CoverageBuy$43.00
(Data available from 4/21/2020 forward)

News Sentiment Rating

0.45 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/23/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/23/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/22/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/22/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/21/2025
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/20/2025
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/22/2025
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/21/2025

Current Sentiment

  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Silverback Therapeutics logo
Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Read More

Today's Range

Now: $14.88
Low: $14.43
High: $15.09

50 Day Range

MA: $12.22
Low: $10.18
High: $14.99

52 Week Range

Now: $14.88
Low: $2.80
High: $8.97

Volume

1,550,448 shs

Average Volume

337,931 shs

Market Capitalization

$536.54 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.6

Frequently Asked Questions

What sell-side analysts currently cover shares of Silverback Therapeutics?

The following equities research analysts have issued reports on Silverback Therapeutics in the last year:
View the latest analyst ratings for SBTX.

What is the current price target for Silverback Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Silverback Therapeutics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Silverback Therapeutics in the next year.
View the latest price targets for SBTX.

What is the current consensus analyst rating for Silverback Therapeutics?

Silverback Therapeutics currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for SBTX.

What other companies compete with Silverback Therapeutics?

Other companies that are similar to Silverback Therapeutics include Mirum Pharmaceuticals, Schrödinger, Metsera, Biohaven and Belite Bio. Learn More about companies similar to Silverback Therapeutics.

How do I contact Silverback Therapeutics' investor relations team?

The company's listed phone number is 206 456 2900 and its investor relations email address is ir@silverbacktx.com. The official website for Silverback Therapeutics is www.silverbacktx.com. Learn More about contacing Silverback Therapeutics investor relations.





Receive Silverback Therapeutics News & Ratings Daily
Sign up to receive the latest news and ratings for Silverback Therapeutics and its competitors with PriceTargets.com’s free daily newsletter.